Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study

NCT02125240 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT02125240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2014
Completion date
July 31, 2021
Enrollment
124 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, egfr positive non-small cell lung cancer